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Background: Transcranial magnetic stimulation (TMS) has been used in both physiological studies and,
more recently, the therapy of Parkinson’s Disease (PD). Prior TMS studies in healthy subjects and other
patient populations demonstrate a slight risk of seizures and other adverse events. Our goal was to
estimate these risks and document other safety concerns speciﬁc to PD patients.
Methods: We performed an English-Language literature search through PudMed to review all TMS
studies involving PD patients. We documented any seizures or other adverse events associated with
these studies. Crude risks were calculated per subject and per session of TMS.
Results: We identiﬁed 84 single pulse (spTMS) and/or paired-pulse (ppTMS) TMS studies involving 1091
patients and 77 repetitive TMS (rTMS) studies involving 1137 patients. Risk of adverse events was low in all
protocols. spTMS and ppTMS risk per patient for any adverse event was 0.0018 (95% CI: 0.0002e0.0066)
per patient and no seizures were encountered. Risk of an adverse event from rTMS was 0.040 (95% CI:
0.029e0.053) per patient and no seizures were reported. Other adverse events included transient head-
aches, scalp pain, tinnitus, nausea, increase in pre-existing pain, and muscle jerks. Transient worsening of
Parkinsonian symptoms was noted in one study involving rTMS of the supplementary motor area (SMA).
Conclusion: We conclude that current TMS and rTMS protocols do not pose signiﬁcant risks to PD pa-
tients. We would recommend that TMS users in this population follow the most recent safety guidelines
but do not warrant additional precautions.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.University of Colorado School
ue, Aurora, CO 80045, USA.
gela.roslawski@ucdenver.edu
-NC-ND license.1. Introduction
Transcranial magnetic stimulation (TMS) is a noninvasive tech-
nique for cortical stimulation that uses electromagnetic induction to
generate a strong ﬂuctuating magnetic ﬁeld which induces intra-
cranial currents [1]. Single pulse (spTMS) and paired-pulse TMS
(ppTMS) studies have been shown to be safe and effective in studying
a variety of measures of motor cortex excitability including resting
M. VonLoh et al. / Parkinsonism and Related Disorders 19 (2013) 573e585574motor threshold, motor evoked potential amplitude, recruitment
curves, cortical silent period, short interval intracortical inhibition,
long interval intracortical inhibition and intracranial facilitation [2].
Studies of Parkinson’s Disease (PD) patients using these techniques
have demonstrated that PD increases net cortical excitability and that
effective therapeutic interventions including medications and sur-
gery may reduce this excitability [3]. Repetitive TMS (rTMS) applies
repeated TMS pulses at set frequencies or patterns to induce changes
in cortical excitability which last longer than the period of stimulus
administration [4]. These alterations have generally been observed as
a decrease in cortical excitability with low-frequency stimulation
(1 Hz) and an increase in cortical excitability with high frequency
rTMS (5 Hz) [5]. Patterned rTMS protocols such as theta-burst
stimulation (TBS) and repetitive paired-pulse stimulation utilize
more complex trains of intermittent bursts and may induce even
more durable alterations in cortical excitability [6].
rTMS has been investigated as a potential therapy for numerous
conditions, including depression, epilepsy, migraine, and PD [7e9].
In PD, rTMS has been studied as an intervention to improve both
motor symptoms, including rigidity and bradykinesia, motor
complications of therapy (e.g. dyskinesias) and non-motor symp-
toms, including depression and speech [10]. In general, beneﬁts
when present have been of small to moderate magnitude and
short-lived. However, given the potential for clinical beneﬁt and
limitations of medical options there is a need for further studies to
further develop rTMS as a therapeutic intervention and to better
deﬁne the longevity, efﬁcacy, and beneﬁt of rTMS [11].
The use of TMS in both healthy and clinical populations has been
associated with several adverse events of varying severity. The
most common are transient headaches and scalp discomfort. Scalp
pain and headaches are thought to be due to activation of scalp
pericranial muscles [2,12]. However, more severe adverse effects
may include mood changes (induction of mania), scalp burns from
electrodes, and induction of seizures [2]. Seizures during TMS are
thought to be a result of cortical pyramidal cell activation, spread of
excitation to neighboring neurons, and overwhelming of inhibitory
mechanisms [13]. Although reviews detailing the safety of TMS use
exist for depression, epilepsy, and migraine, no such review exists
for TMS use in PD [8,14,15]. Although PD is not associated with an
increased risk of seizures, other neurophysiological changes may
confer unique risks of TMS in the PD population including changes
in cortical excitability and reductions in motor cortex inhibition
[16]. Therefore, the purpose of this article is to provide a safety
proﬁle of TMS in PD for researchers and clinicians by reviewing the
literature for any adverse events associated with TMS on PD
patients.
2. Methods
2.1. Literature review
A literature search for English-language studies on TMS use in PDwas conducted
through PudMed. Review articles were excluded. The searches used included the
following key words: transcranial magnetic stimulation, TMS, rTMS, Parkinson, Par-
kinson’s disease, silent period, Deep Brain Stimulation and theta burst. All applicable
articles were reviewed for patient demographics (gender, age, medication status),
TMS protocol used (TMSmodality, method of localization, number of stimuli, stimuli
intensity, coil type, and coil position) and adverse events reported. The review was
conducted between 1992 and December 2011.
2.2. Statistical analysis
We computed the proportion estimate of crude risk and 95% conﬁdence in-
tervals of seizures and other adverse events separately. We also separated single
pulse and rTMS studies. Risks were calculated as per-person risk and per TMS ses-
sion. Conﬁdence intervals were calculated utilizing the Clopper-Pearsonmethod in R
software version 2.14.1. Fisher’s exact test was used to compare crude risks between
groups.3. Results
3.1. Single and paired-pulse TMS
We identiﬁed 84 studies utilizing single or paired-pulse tech-
niques in PD patients. This included 71 single-pulse protocols and 24
paired-pulse protocols including 1091 patients with PD [10,17e97]
Of these studies, 2 reported adverse events and 1 reported a tran-
sient change in motor performance. No seizures were reported, thus
the crude risk of seizures is 0 (95% CI: 0.0000e0.0034). The risk of
any adverse event during spTMS or ppTMS is 0.0018 (95% CI:
0.0002e0.0066) per patient.
Regarding adverse events potentially related to PD, Boylan et al.
described a worsening of tremor in one patient following spTMS to
the motor cortex during localization [98]. As this patient was also
described to have an exaggerated startle response we suspect that
the change in tremor may be more related to acute stress and not
a speciﬁc physiologic reaction. Cunnington et al. reported a tran-
sient increase in movement time required to complete a button
pressing task in six patients following 100% maximum stimulator
output (MO) spTMS of the SMA [62]. The slowing of movement only
occurred when stimulation was administered early in the move-
ment and was not found to be statistically correlated with patient
age, severity of symptoms, or duration of disease. The authors hy-
pothesized that this slowing reﬂected interruption of the SMA’s
role in movement planning and is supported by other TMS research
investigating the SMA in healthy populations [99].
Regarding other adverse events, Benninger et al. reported the
occurrence of ipsilateral stimulation of cranial nerve (CN) VII in one
patient following spTMS administered between trains of 50 Hz
rTMS of M1, however the patient experienced no cranial nerve
stimulation during the 50 Hz rTMS itself suggesting that this may
be a coil placement issue [100].
3.2. rTMS
rTMS refers to repetitive TMS given either continuously at a low-
frequency or in intermittent trains at higher frequencies. Theta-Burst
Stimulation (TBS) refers to a newer protocol where TMS stimulation
is given in bursts of triplets at 50 Hz repeated in the theta range
(5 Hz) either continuously (cTBS) or intermittent trains of 2 s (iTBS)
[101]. We identiﬁed 77 rTMS and TBS studies involving PD patients.
This included 81 separate rTMS protocols and 8 TBS protocols
involving a total of 1137 patients and 11672 rTMS sessions
[10,29,30,47,51,66,80,98,100,102e164]. Tables 1 and 2 summarizes
the demographic characteristics of these patients, study design, TMS
parameters and any adverse events for rTMS and theta-burst studies
respectively. Of these studies, 14 reported the occurrence of an
adverse event. There were no seizures reported. 51 adverse events
were attributed to rTMS protocols. Of the 63 articles which did not
report an adverse event, 33 protocols stated a lack of adverse events.
The remaining 39 protocols neither stated nor denied the occurrence
of any adverse events associated with rTMS or TBS. Out of 77 studies
4 reported scalp pain during treatment [98,102,118,145], 5 reported
mild transient headaches [106,112,117,142,145], plus 2 studies with
an unstated number of headaches [106,112,117,142,145], 2 studies
reported worsening performance of a motor task [98,133], 1 TBS
study reported transient (<5 min) tinnitus [102], 1 study reported
nausea [112], and 1 study reported transient increase in pre-existing
back pain [113].
The crude risk of seizures in PD subjects is thus 0 (95% CI: 0e
0.0032)per person and 0 (95%CI: 0e0.0003) per rTMSor TBS session.
The crude risk of other adverse events in PD subjects is 0.040 (95% CI:
0.029e0.053) per person and 0.0039 (95% CI: 0.0028e0.0052) per
rTMS or TBS session. Comparing protocols with a single session
Table 1
rTMS data.
Author Year No. of
subjects
On/Off
medication
Age rTMS
modailty
Method of
localization
rTMS
frequency
No. of stimuli
per session
Intensity Coil type Intertrain
interval
Session
schedule
Total
number
of sessions
Target Adverse
events
Gonzalez-
Garcia
et al. [168]
2011 17 On 57e70 High
frequency
NR 25 Hz 200 (M1); 2000
(occipital lobe)
80% RMT Fig8 NR 15 sessions
over 3 months
255 M1; occipital
lobe
NR
Kodama
et al. [154]
2011 1 On 45 Low
frequency
Maximum MEP
hotspot
0.9 Hz 200 (M1 hand);
300e600
(M1 leg)
110% AMT Fig8 NR 8 sessions over
2 months
(M1 hand);
12 sessions
over 3 month
(M1 leg)
20 M1 hand;
M1 leg
None
Rektor
et al. [163]
2010 10 NR NR Low
frequency
NR 1 Hz 600 NR NR NR 1 session 10 DLPFC; IFC NR
Hartelius
et al. [148]
2010 10 Off 39e67 High
frequency
Maximum MEP
hotspot
10 Hz 2000 90% RMT Fig8 4 min 2 sessions
over 2
consecutive days
10 M1 NR
Pal et al. [106] 2010 12 On/Off 59e70 High
frequency
NR 5 Hz 600 90% RMT Fig8 20 s 10 sessions over
10 days
120 DLPFC Mild transient
headache
(n ¼ 2)
Kang
et al. [150]
2010 11 On/Off 48e75 High
frequency
NR 25 Hz 1500 100% MT Fig8 10 s 2 sessions 22 M1 NR
Arias
et al. [138]
2010a 9 On NR Low
frequency
NR 1 Hz 100 90% RMT C 5 min 10 sessions over
10 days
90 Vertex NR
Suppa
et al. [160]
2010 14 On/Off 52e77 High
frequency
Maximum MEP
hotspot (M1);
2.5 cm anterior
to the M1
hotspot (PMd)
5 Hz 1500 (PMd);
150 (M1)
90% RMT
(PMd); 120%
RMT (M1)
Fig8 1 min 2 sessions
separated
by 5 days
28 PMd; M1 None
9 On/Off 45e63 High
frequency
Maximum MEP
hotspot
5 Hz 450 120% RMT Fig8 1e2 min 1 session 9 M1 None
5 On 54e73 High
frequency
Maximum MEP
hotspot
1 Hz 1500 90% AMT Fig8 1 min 2 sessions
separated by
at least 5 days
10 PMd None
Arias
et al. [137]
2010b 9 On NR Low
frequency
NR 1 Hz 100 90% RMT C 5 min 10 sessions
over 10 days
90 Vertex NR
Borgheres
et al. [169]
2010 1 NR 79 High
frequency
NR 5 Hz 15 120% RMT Fig8 NR 1 session 1 M1 NR
Balaz
et al. [139]
2010 18 On 55.8  6.52 Low
frequency
Frameless
stereotaxy
1 Hz 600 80% RMT Fig8 NR 1 session 18 DLPFC (n ¼ 8);
IFC (n ¼ 10)
NR
Filipovic
et al. [104]
2010a 9 On 48e73 Low
frequency
Maximum MEP
hotspot
1 Hz 1800 90% RMT Fig8 1 min 4 sessions
over 4 days
36 M1 None
Filipovic
et al. [146, 162]
2010b 10 Off 49e74 Low
frequency
Maximum MEP
hotspot
1 Hz 1800 90% RMT Fig8 1 min 4 sessions
over 4 days
40 M1 NR
Gruner
et al. [170]
2010 15 On 56e81 Low
frequency
Maximum MEP
hotspot
1 Hz 900 90% RMT Fig8 None 1 session 15 M1 None
Jacobs
et al. [149]
2009 8 Off 62  10 Low
frequency
5 cm anterior to
the TA
hotspot
(SMA); 2.5 cm
anterior to the
FDI
hotspot
1 Hz 1800 80% RMT Fig8 NR 2 sessions
separated
by 1 week
16 SMA; DLPFC NR
Furukawa
et al. [147]
2009 6 On 62e71 Low
frequency
Maximum MEP
hotspot
0.2 Hz 100 120% MT C NR 12 sessions
over 3 months
72 M1 NR
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Table 1 (continued )
Author Year No. of
subjects
On/Off
medication
Age rTMS
modailty
Method of
localization
rTMS
frequency
No. of stimuli
per session
Intensity Coil type Intertrain
interval
Session
schedule
Total
number
of sessions
Target Adverse
events
Narayana
et al. [108]
2009 1 On 59 High
frequency
Image-based
robotically
positioned TMS
4 Hz 400 110% MT NR 5 s 10 sessions 10 M1 None
van Dijk
et al. [161]
2009 13 On 46e75 High
frequency
Maximum MEP
hotspot (M1); 5 cm
posterior to MEP
hotspot (parietal
cortex); 2.5 cm
anterior to MEP
hotspot (prefrontal
cortex)
5 Hz 500 80% RMT Fig8 20 s 10 sessions
over 10 days
130 Parietal
cortex (n ¼ 8);
M1 or
premotor
cortex (n ¼ 7)
None
Baumer
et al. [109]
2009 15 On/Off 63.1  6.8 Low
frequency
Maximum MEP
hotspot
1 Hz 1200 80% AMT Fig8 NA 4 sessions 60 PMd NR
Benninger
et al. [100]
2009 10 On 50e77 High
frequency
Maximum MEP
hotspot
50 Hz 1000 60% - 90%
RMT
C NR 1 session 10 M1 None
Sedlackoa
et al. [110]
2009 10 Off 52e79 High
frequency
Frameless
stereotaxy
10 Hz 1350 100% RMT Fig8 10 s 3 sessions
separated
by 10 min
30 DLPFC;
occipital
cortex; dorsal
premotor
cortex
None
Rothkegel
et al. [112]
2009 22 On/Off 34e76 Low
frequency
Maximum MEP
hotspot
0.5 Hz 600 80% RMT Fig8 NA 1 session 22 M1 Headache
(n ¼ 2), nausea
(n ¼ 1)High
frequency
Maximum MEP
hotspot
10 Hz 2000 80% RMT Fig8 50 s 1 session 22 M1
Brusa
et al. [143]
2009 8 On 52e75 Low
frequency
1 cm anterior
to Cz
1 Hz 900 65% MO Fig8 NA 10 sessions
over 2 weeks
80 M1 NR
Cardoso
et al. [142]
2008 11 Off 67  8.3 High
frequency
5 cm anterior to
optimal stimulation
of abductor pollicis
brevis
5 Hz 3750 120 % MT Fig8 NR 12 sessions
over 4 weeks
132 DLPFC Headache
(equally
distributed
in both rTMS
and rTMS
sham groups
Filipovic
et al. [171]
2008 5 On 48e74 Low
frequency
Maximum MEP
hotspot
1 Hz 1800 90% AMT Fig8 1 min 4 sessions
over 4 days
20 M1 None
Rodrigues
et al. [47]
2008 6 On/Off 62e73 Low
frequency
Maximum MEP
hotspot
0.2 Hz 440 130% RMT Fig8 5 s 2 sessions,
1 on and 1
off medication
12 M1 None
Hamada
et al. [113]
2008 55 On 39e82 High
frequency
3-cm anterior
to maximum MEP
hotspot for tibialis
anterior
5 Hz 1000 110% AMT Fig8 50 s 8 sessions
over 8 weeks
440 SMA Lower back
pain increased
(n ¼ 1)
Rektorova
et al. [114]
2008 6 On 67.3  7.7 High
frequency
Optimum activation
of FDI or TA
10 Hz 1350 90% RMT C NR 5 sessions
over 5
consecutive
days
30 DLPFC None
Fierro
et al. [66]
2008 14 On/Off 48e82 High
frequency
Maximum MEP
hotspot
10 Hz 500 90% MT Fig8 30 s 2 sessions 28 M1 NR
Kim
et al. [152]
2008 9 Off 43e68 High
frequency
NR 5 Hz 75 90% RMT Fig8 10 s 2 sessions
over 2
consecutive
days
18 M1 NR
Epstein
et al. [115]
2007 14 On/Off 42e78 High
frequency
MEP w/ lowest
threshold
10 Hz 1000 110% RMT Custom
iron core
coil
25 s 20 sessions
over 10 days
280 M1 None
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Kormos [172] 2007 7 Off 62e79 High
frequency
NR 20 Hz 2000 80% MT NR 28 s 10 sessions
over 2 weeks
70 DLPFC None
Rektorova
et al. [157]
2007 6 On 63.7  7.7 High
frequency
NR 10 Hz 1350 90% RMT Fig8 NR 5 sessions
over 5 days
30 MC, DLPFC NR
Khedr
et al. [151]
2007 22 Off 45e85 High
frequency
NR 25 Hz 2000 100% RMT Fig8 50 s 36 sessions
over 6 days
792 M1 NR
Anninos
et al. [116]
2007 30 Off 49e80 High
frequency
NR 8e13 Hz 2880e4680 1e7.5 pT C NR 3 sessions,
1 in lab and
2 self-
administered
at patient's
home
90 Left and right
temporal
regions,
frontal and
occipital
regions,
vertex
None
Loscher
et al. [155]
2007 8 On 58.5  5.3 High
frequency
NR 5 Hz 100 MEP ¼
0.5e1 mV
Fig8 1 min 1 session 8 M1 NR
Del Olmo
et al. [144]
2007 8 On 54e74 High
frequency
5 cm anterior
to maximum
MEP for FDI
10 Hz 450 90% RMT Fig8 10 s 10 sessions
over 10 days
80 DLPFC NR
Fregni
et al. [135]
2006 13 On 65.2  7.9 High
frequency
5 cm anterior to
maximum MEP
for APB
15 Hz 3000 110% RMT Fig8 10 s 10 sessions
over 2 weeks
130 DLPFC NR
Brusa
et al. [141]
2006 10 Off 61  8.04 Low
frequency
3 cm anterior
to Cz
1 Hz 900 90% RMT Fig8 NA 2 sessions 20 SMA None
2006 10 On 61  8.04 Low
frequency
3 cm aterior
to Cz
1 Hz 900 90% RMT Fig8 NA 5 sessions
over 5 days
50 SMA None
Cincotta
et al. [29]
2006 3 NR 60e82 High
frequency
Maximum MEP
hotspot
5 Hz 15 120% RMT Fig8 NA 4 sessions 12 M1 NR
Morgante
et al. [30]
2006 16 On/Off 50e80 Low
frequency
Maximum MEP
hotspot
0.1 Hz 20 MEP ¼ 1mV Fig8 NA 6 sessions, 3
on medication
and 3 off
medication
96 M1 NR
Khedr
et al. [117]
2006 55 Off 30e85 High
frequency
NR 10/25 Hz 2000 100% MT Fig8 50 s 36 sessions,
6 sessions
per day for
6 days
1980 Bilateral M1
for lower
limbs,
Bilateral M1
for the hand
Mild, transient
headache in
some patients
Lomarev
et al. [118]
2006 18 On 63  10 High
frequency
NR 25 Hz 1200 100% MT Fig8 NR 8 sessions over
a 4-week
period
144 Left and right
motor and
DLPFC
Intolerable
pain (n ¼ 1)
Dias
et al. [64]
2006 11 On 68.47  4.75 High
frequency
Maximum MEP
hotspot
15 Hz 3000 110% MT Fig8 10 s 10 sessions
over 2 weeks
110 DLPFC None
2006 8 On 61.31  8.46 High
frequency
Maximum MEP
hotspot
5 Hz 2250 90% MT Fig8 5 s 1 session 8 M1 None
Strafella
et al. [119]
2005 7 Off 40e66 High
frequency
MEP w/ lowest
threshold
10 Hz 600 90% RMT C 10 s 2 sessions
over 2 days
14 M1 NR
Boggio
et al. [120]
2005 13 Off NR High
frequency
Maximum MEP
hotspot
15 Hz 3000 110% MT Fig8 NR 10 sessions
over 2 weeks
130 Left DLPFC None
Koch
et al. [153]
2005 8 Off 48e73 Low
frequency
3 cm anterior
to Cz
1 Hz 900 90% RMT Fig8 NA 1 session 8 SMA NR
High
frequency
3 cm anterior
to Cz
5 Hz 900 110% RMT Fig8 40 s 1 session 8 SMA NR
Mir
et al. [80]
2005 9 On/Off 47e73 High
frequency
Maximum MEP
hotspot
5 Hz 1500 90% AMT Fig8 1 min 2 sessions 18 PMd None
Buhmann
et al. [51]
2004 16 On/Off 58.4  10.5 Low
frequency
Maximum MEP
hotspot
1 Hz 1200 80% AMT Fig8 NA 2 sessions
over 2 weeks
32 PMd None
Lefaucheur
et al. [10]
2004 12 Off 51e76 Low
frequency
Maximum MEP
hotspot
0.5 Hz 600 80% RMT Fig8 NA 1 session 12 M1 None
High
frequency
Maximum MEP
hotspot
10 Hz 2000 80% RMT Fig8 50 s 1 session 12 M1 None
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Table 1 (continued )
Author Year No. of
subjects
On/Off
medication
Age rTMS
modailty
Method of
localization
rTMS
frequency
No. of stimuli
per session
Intensity Coil type Intertrain
interval
Session
schedule
Total
number
of sessions
Target Adverse
events
Mally
et al. [156]
2004 46 On 63.9  9 Low
frequency
NR 1 Hz 50 25% MO
(MO ¼ 2.3T)
C NA 42 sessions
over 3 years
administered
in 7 sessions
over 7 days
1932 Vertex None
Fregni
et al. [121]
2004 21 On 50e80 High
frequency
NR 15 Hz 3000 110% MT Fig8 NR 10 sessions
over 10 days
210 Left DLPFC NR
Koch
et al. [122]
2004 20 Off 61  6.83 High
frequency
3 cm anterior
to vertex (SMA),
Intersection of
coil loops at
F4 (DLPFC)
5 Hz 250 100% MT Fig8 30 s 2 sessions
on 2 separate
days
40 SMA and
right DLPFC
NR
Bornke
et al. [140]
2004 12 Off 37 - 74 High
frequency
NR 10 Hz 1000 90% RMT Fig8 10 s 2 sessions
over 4 days
24 M1 None
Ikeguchi
et al. [123]
2003 12 On 51e78 Low
frequency
F3 or F4 of the
international
10e20 system
0.2 Hz 30 70% MO C NA 6 sessions
over 2 weeks
72 Frontal
(L middle
frontal gyrus,
R inferior
frontal gyrus);
Occipital
(L lingual
gyrus,
R posterior
lobe of
cerebellum)
None
Khedr
et al. [124]
2003 19 Off 36e70 High
frequency
Maximum MEP
hotspot
5 Hz 2000 120% MT Fig8 NR 10 sessions
over 10 days
190 M1 (EDB) 1000
pulses; M1
(hand) 500
pulses/
hemisphere
NR
Okabe
et al. [125]
2003 85 (1/3
received
sham)
On 67.2  8.2 Low
frequency
NR 0.2 Hz 100 110% AMT C NA 8 sessions
over 8 weeks
680 M1 and
occipital
cortex
NR
Gilio
et al. [126]
2002 15 On/Off
(4 patients
only off;
the rest
off/on)
46e76 High
frequency
NR 5 Hz 40 (Off/On
medication);
160 (Off
medication
only)
120% RMT Fig8 1 min 2 sessions
in 1 day
30 M1 NR
Sommer
et al. [127]
2002 11 On 35e77 Low
frequency
Maximum MEP
hotspot
1 Hz 900 120% RMT Fig8 NA 3 sessions
over 3 days
33 M1 None
Dragasevic
et al. [145]
2002 10 On 46e72 Low
frequency
6 cm anterior
to point of motor
threshold
determination
0.5 Hz 100 110% MT C 1 min 20 sessions
over 10 days
200 Prefrontal
area
Light burning
sensations
over the scalp
(n ¼ 4); mild
tension
headache
(n ¼ 3)
Boylan
et al. [98]
2001 10 Off 55e77 High
frequency
Visible muscle
twitch
10 Hz 2000 110% MT,
68e78% MT
for 3 patients
Fig8 55 s 1 session 10 SMA Scalp
discomfort
at 110%
maximum
MEP (n ¼ 3);
Subclinical
worsening of
complex and
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preparatory
movement
(spiral
drawing)
following
rTMS to SMA
(n ¼ 5)
Shimamoto [128] 2001 9 On 53e79 Low
frequency
NR 0.2 Hz 60 78%
MO (700V)
C NA 8 sessions
over 8 weeks
72 Frontal area NR
Siebner
et al. [129]
2000a 10 Off 57  11 High
frequency
Maximum MEP
hotspot
5 Hz 2250 90% RMT Fig8 10 s 1 session 10 M1 None
Siebner
et al. [130]
2000b 10 Off 41e75 High
frequency
Maximum MEP
hotspot
5 Hz 2250 130% RMT Fig8 10 s 1 session 10 M1 NR
Tergau
et al. [164]
1999 7 On 54e73 Low
frequency
Maximum MEP
hotspot
1 Hz 500 90% MT C NA 1 session 7 M1 NR
High
frequency
Maximum MEP
hotspot
5 Hz 500 90% MT C 30 s 1 session 7 M1 NR
High
frequency
Maximum MEP
hotspot
10 Hz 500 90% MT C 20 s 1 session 7 M1 NR
High
frequency
Maximum MEP
hotspot
20 Hz 500 90% MT C 45 s 1 session 7 M1 NR
Mally
et al. [131]
1999a 49 On NR Low
frequency
NR 1 Hz 30, 60 15e30% MO C NA 10 sessions
over 10 days,
14 sessions
over 14 days
1176 Vertex None
Ghabra
et al. [133]
1999 11 Off 48e70 High
frequency
Maximum MEP
hotspot
5 Hz NR 90% RMT Fig8 NR 2 sessions 22 M1 Muscle
jerks during
motor task
(n ¼ 11)
Mally
et al. [132]
1999b 10 On 56e73 Low
frequency
NR 1 Hz 30 20% MT C NR 20 sessions
over 10 days
200 Vertex NR
Siebner
et al. [134]
1999 12 Off 41e74 High
frequency
Maximum MEP
hotspot
5 Hz 2250 90% RMT Fig8 10 s 2 sessions
over 2 days
24 M1 None
Sandyk [158] 1998 2 On 49, 73 High
frequency
NR 5, 7 Hz 6000,
8400
7.5 pT NR NR 4 5 Hz and
4 7 Hz
sessions
over 4 days
16 NR NR
Pascual-Leone
et al. [135]
1994 6 On/Off 48e73 High
frequency
Maximum MEP
hotspot
5 Hz NR 10% RMT Fig8 NR 3 sessions 18 M1 None
Totals 1068 11,198 17 scalp
pain, 12 mild
transient
headaches,
1 study with an
unstated
number of
headaches,
16 worsening
performance
of a motor task,
1 nausea, and
1 transient
increase in
pre-existing
back pain
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Table 2
Theta burst stimulation studies.
Author Year Number
of subjects
On/Off
medication
Age TMS parameters Adverse events
Stephani et al. [159] 2011 8 On 62.2  8.3 3 sessions at least one week apart of M1 iTBS,
sham iTBS and tRNS given at 80% rMT for 10 min.
NR
Benninger et al. [102] 2011 13 On 62.1  6.9 8 sessions over two consecutive weeks of iTBS
over bilateral M1 and DLPFC at 80% aMT for
600 pulses per site per session and 4800 total pulses.
Transient tinnitus (<5 min, N ¼ 1)
and occasional local pain during
stimulation
Suppa et al. [103] 2011 20 On 48e76 1 session of iTBS over M1 at 80% aMT for a total
of 600 pulses.
No adverse effects
Eggers et al. [107] 2010 8 Off 60e78 One session of cTBS over m1 at 80% aMT for a total
of 600 pulses.
NR
Koch et al. [111] 2009 20 On 64.2  5.4 10 sessions of bilateral cerebellar cTBS at 80% aMT
for 600 pulses per side per session and
12,000 total pulses.
No adverse effects
Rothkegel et al. [112] 2008 22 Both 34e76 5 sessions on 5 consecutive days over M1 including
sham iTBS (600 pulses), high frequency rTMS (10 Hz
for 2000 pulses at 80%rMT), low frequency rTMS
(0.5 Hz at 80% rMT for 600 pulses), cTBS (600 pulses
at 80% aMT) and iTBS (600 pulses at 80% aMT)
NR
Total 91 1 episode transient tinnitus;
unspeciﬁed number with
occasional local pain
aMT e active motor threshold; cTBS e continuous theta burst stimulation; DLPFC e dorsolateral prefrontal cortex; iTBS e intermittent theta burst stimulation; M1 e motor
cortex; rMT e resting motor threshold; tRNS e Transcranial random noise stimulation.
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cant increase in risk with multiple sessions (Fisher’s exact test,
p < 0.001) suggesting that risk is at least partially cumulative over
sessions rather than an all or none occurrence for certain high-risk
subjects.
Regarding adverse events potentially related to PD, motor
symptomswere shown toworsen of selectedmotor tasks inpatients
following certain rTMS protocols (N ¼ 16). Boylan et al. reported
worsening of spiral drawing in ﬁve patients following 10Hz rTMS of
the SMA [98]. This ﬁnding may relate to the role of the SMA in
movement preparation as demonstrated in control subjects. Ghabra
et al. reported muscle jerks during 90%, RMT 5 Hz rTMS over M1
such that eleven patients could not complete a concurrent Grooved
Pegboard task. This “jerking” likely reﬂected MEPs induced with
a lowering of motor threshold when subjects activated motor cor-
tex during the skilled motor task. Upon rTMS intensity reduction to
75e85% RMT all patients were able to complete the task. One
patient in this study also noted a worsening of action tremor at the
higher stimulation intensity which resolved at 75% RMT rTMS
intensity and may reveal a potential interaction between motor
cortex activation, whether external or internal, and action tremor.
Regarding adverse events not related to PD, the most common
adverse effects reported were headache (N ¼ 7) and local pain
(N¼ 17). Authors gave the following descriptions of adverse events.
Pal et al. reported the occurrence of mild transient headache in two
patients which required neither interruption of study or medi-
cation attention following 5 Hz rTMS of M1 [106]. Rothkegel et al.
reported headache in two patients following TMS of M1, though the
modality which caused the side effects was not speciﬁed out of the
four used (rTMS at 0.5 Hz and 10 Hz, iTBS, and cTBS) [112]. Cardoso
et al. reported an unspeciﬁed number of headaches which were
spread equally amongst the rTMS group and the sham rTMS group
using a sham coil [142]. Khedr et al. reported the occurrence of mild
transient headache following 25 Hz rTMS of M1, though an exact
number of patients experiencing the event was not stated [117].
Dragasevic et al. reported mild tension headache in 3 patients
following 0.5 Hz rTMS of the prefrontal area [145]. Boylan et al.
reported scalp discomfort (N ¼ 3) following 10 Hz rTMS of SMA
[98]. Benninger et al. reported scalp pain associated with DLPFC
stimulation in nine subjects following intermittent theta-burst
stimulation (iTBS) of the primary motor cortex (M1) [102] [100].Lomarev et al. reported intolerable pain located under the coil
position in one patient following 25 Hz rTMS of M1 and dorso-
lateral prefrontal cortex, due to which the patient dropped out of
the study [118]. Dragasevic et al. reported light burning sensations
over the scalp in four patients following 0.5 Hz rTMS of the pre-
frontal area [145]. Boylan et al. reported scalp discomfort in three
patients following 10 Hz rTMS of the SMA which was alleviated by
reducing the stimulus intensity from 110% motor threshold (MT) to
68%e78% MT [98].
Other adverse events reported included tinnitus (N ¼ 1), nausea
(N ¼ 1), and an increase in previously acquired lower back pain
(N ¼ 3). Benninger et al. reported a nonpulsatile left-sided tinnitus
for a few minutes in one subject following intermittent theta-burst
stimulation (iTBS) of the primary motor cortex (M1) [102]. Roth-
kegel et al. reported nausea in one patient following TMS of M1,
though the modality which caused the side effects was not speci-
ﬁed out of the four used (rTMS at 0.5 Hz and 10 Hz, iTBS, and cTBS)
[112]. Hamada et al. reported an increased sensation of back pain
which existed prior to treatment in one patient following 5 Hz
rTMS of the supplementary motor area (SMA) [113].
A number of events which either did not directly result in
negative outcomes for the patient or were not attributed to the
rTMS procedure were also reported. Due to this, these events were
not included in the risk assessments, but are included here for
completeness. Beninnger et al. reported one patient with residual
muscle activity and possible spread of excitation from arm to
lower extremity muscles by clinical observation following 50 Hz
rTMS [100]. This subject also had a slight increase in left temporal
spikes monitored by electroencephalography (EEG) but had oc-
casional bitemporal spikes at baseline and upon further ques-
tioning after the rTMS session mentioned a prior car accident with
blunt head trauma and possible loss of consciousness. Epstein
et al. reported the occurrence of falls (n ¼ 4), a recurrence of
paroxysmal atrial ﬁbrillation (n ¼ 1), and unilateral hip pain un-
related to any acute injury (n ¼ 1) during a trial of 10 Hz rTMS of
M1. However these events were not temporally related to the
rTMS and thus not considered side effects of rTMS treatment [115].
Mally et al. reported the occurrence of dystonia in four patients
which was thought to be a result of drug treatment with levodopa
and extended release levodopa and not a result of 1 Hz rTMS at
the vertex [131].
Table 3
TMS use in PD Patient's with STN DBS devices.
Author Year Number
of subjects
On/Off
medication
On/Off
DBS
Age TMS parameters Adverse events
Balaz et al. [139] 2010 18 On Off 55.8  6.5 1 session of rTMS at 80% rMT at 1 Hz
over either IFC or DLPFC for 600 total pulses
NR
Kuriakose et al. [19] 2010 8 On Both 52e75 1 session of single pulse TMS over M1 delivered
every 6 seconds in 3 different coil orientations
(AP, PA and perpendicular) following DBS pulses
for approximately 180 total pulses
NR
Rektor et al. [163]a 2010 10 NR Off NR 1 session of 1 Hz rTMS for 600 pulses over either
right IFC or DLPFC; Intensity NR
NR
Baumer et al. [109] 2009 15 Both Both 60.3  6.3 4 single pulse TMS sessions over M1 consisting
of rMT determination and 10 pulses at 150% of
rMT over motor hotspot for SP determination
NR
Narayana [108] 2009 1 NR Off 59 10 sessions of 4 Hz rTMS over left PMd at 110%
rMT delivered in 5 second trains with a 5 second
intertrain interval. 20 trains were given per session
for a total of 4000 pulses
No adverse effects.
TMS mimicked aspects
of DBS induced speech
dysfunction which was
the intended effect
(virtual lesion)
Gaynor et al. [22] 2008 9 On Off 50e69 1 session including 30e50 single pulses every 5
seconds over one or both M1 and left SMA at 95%
and 115% rMT
NR
Fraix et al. [68] 2008 15 Off Both 60  11 1 session over M1 of single pulse (SP, rMT, aMT,
CMCT) and paired e pulse (SICI, ICF) measures
for approximately 180 total pulses
No adverse effects
Potter-Nerger et al. [20] 2008 10 Off Both 58.3  8.3 1 session of 95% aMT single pulses over M1 (soleus
hotspot) for approximately 60 total pulses
NR
Sailer et al. [173] 2007 7 Both Both 56.1  6.3 1 session of single pulse TMS at rMT over M1
paired with median nerve stimulation to measure
SAI and LAI for approximately 80 total pulses
NR
Compta et al. [61] 2006 3 Off Off NR 1 session of suprathreshold SP determination
for approximately 10 total pulses
NR
Hidding et al. [28] 2006 8 Off Off 43e69 1 session of RC and CMCT over M1 at 110%-150%
rMT for approximately 50 total pulses.
NR
Kuhn et al. [32] 2004 5 On Off 56.8  3.0 1 session of single pulse TMS over M1 above rMT
with or without acoustic stimulation. Estimated
20e50 total pulses
NR
Dauper et al. [53] 2002 8 Both Both 59.3  10.0 4 sessions of single pulse (MEP, SP) and paired-pulse
(SICI, ICF) at 120% rMT for approximately 80 total pulses
No adverse events
Cunic et al. [40] 2002 9 On Both 41e78 3 sessions of single pulse (MT, RC, SP) and paired-pulse
(SICI, LICI, ICF) M1 stimulation at 100e150% rMT at rest
and active contraction for estimated 360 total pulses
No adverse effects
Pierantozzi et al. [83] 2002 4 (implanted
in both bilateral
STN and GPI)
Both Both 49e60 4 sessions of single pulse (rMT) and paired-pulse (SICI)
at 70%-120% rMT for approximately 120 total pulses
NR
Total 122 NR
Abbreviations: aMT e active motor threshold; CMCT e central motor conduction time; DBS e Deep Brain Stimulation; ICF e intracortical facilitation; LAI e long latency
afferent inhibition; M1 e primary motor cortex; MEP e motor evoked potential; NR e not reported; PMd e dorsal premotor cortex; RC e recruitment curve; rMT e resting
motor threshold; rTMSe repetitive transcranial magnetic stimulation; SAIe short latency afferent inhibition; SICIe short intracortical inhibition; SMAe supplemental motor
area; SP e silent period; STN e Subthalamic Nucleus; TMS e Transcranial Magnetic Stimulation.
a May overlap patients in Balaz study.
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144,150,162] (N ¼ 142) and TBS [102,107,111,112,159] (N ¼ 58)
protocols. Of these sham exposures, one patient receiving sham
rTMS over SMAwithdrew due to perceivedworsening of symptoms
[113] and one study reported a similar incidence of mild headaches
in their real and sham 5 Hz DLPFC rTMS groups [142]. While the
number of adverse events for both real and sham rTMS are small,
Fisher’s exact test (P > 0.05) does not reveal a signiﬁcant difference
between crude rates of side effects and suggests that caution may
be warranted when attributing side effects observed in studies to
the physiological effects of rTMS.
3.3. TMS in patients with deep brain stimulators
In 1999 Kumar et al. tested TMS pulses delivered over DBS
leads embedded in conduction gel and directly over stimulators to
demonstrate that TMS in DBS patients did not effect DBS leads but
could disrupt stimulator function if stimulated directly over the
stimulator device [165]. Since that time there have been a numberof studies using TMS in PD patients following deep brain stimu-
lation (DBS) surgery of the subthalamic nucleus (STN; see Table 3)
with no adverse events reported in 122 subjects. The crude
risk of any adverse event in PD STN DBS subjects is thus 0 (95% CI:
0e0.0298) per person. While only one of these studies included
patients who also had globus pallidus interna (GPI) DBS [83],
studies in dystonia subjects with GPI DBS would suggest that these
patients would also be reasonable candidates for future DBS
research [166].
4. Conclusions
TMS has been shown to be a useful technique for studying the
neurophysiology of PD and shows potential in the treatment of
motor and non-motor symptoms. Our review of the literature,
including 2228 patients, revealed that both TMS and rTMS do not
carry signiﬁcant risk of adverse events in the PD population. Based
on our review, we would suggest that TMS and rTMS may have
similar risks to those found in the general population and that these
M. VonLoh et al. / Parkinsonism and Related Disorders 19 (2013) 573e585582risks, while low, do increase over multiple sessions. We would
recommend that TMS users in this population follow the most
recent safety guidelines but do not warrant additional precautions.
We would however recommend that rTMS studies in PD patients
monitor for motor function, particularly with SMA stimulation. We
would also recommend that EEG and EMG monitoring be utilized
for novel stimulation paradigms, as exempliﬁed by Benninger et al.
but do not feel that this level of monitoring needs to be used rou-
tinely [100]. Finally, preliminary evidence from 122 PD patients
with DBS implants similarly suggests that TMS does not carry
a signiﬁcant risk in this population either.
One unique issue raised in this review is the potential for wor-
sening motor symptoms with certain spTMS and rTMS paradigms
[62,98]. The Cunnington et al. spTMS study’s ﬁndings of increased
time to complete a movement was attributed to a disturbance of
the SMA’s role in motor planning due to the occurrence of the
adverse event only when administered early in the movement [62].
Detrimental effects on spiral drawing and the preparatory phase of
movement due to physiological disturbance of SMA has been
observed in studies prior to Boylan et al., including the Cunnington
et al. study on PD patients [62,167]. The Boylan et al. study suggests
that rTMSmay be able to make such disruptions persist beyond the
initial stimulus [98]. However, Hamada et al. found that SMA
stimulation resulted in improvement of motor symptoms in PD
patients as measured by UPDRS scores [113]. There are several
possible causes for the difference between the two study’s ﬁndings.
Hamada et al. used a 5 Hz stimulation frequency as compared to
Boylan et al. using 10 Hz [98,113]. In addition, Hamada et al.
delivered only 1000 stimuli per session, while Boylan et al. deliv-
ered 2000 stimuli [98,113]. The increase in rTMS intensity and total
number of stimuli may have caused Boylan et al. to elicit a negative
outcome due to excessive excitation of the SMA. Another potential
difference lies in the time course of the two studies. Boylan et al.
only delivered 2 sessions at least oneweek apart [98]. Hamada et al.
however did not see improvement of motor symptoms in their
patients until at least 4 consecutive weeks of rTMS treatment [113].
Thus it is possible that reduction of risk and presence of beneﬁt in
rTMS of the SMAwill only be achieved by lower intensity treatment
over a longer timeframe. The conﬂicting results between these two
studies merit further investigation of rTMS stimulation of the SMA
in PD patients. We therefore recommend that rTMS studies in PD
patients monitor for motor ﬂuctuations and worsening.
All other adverse events attributed to rTMS were minor and no
studies reported the need for medical care in response to an event.
Out of 1137 patients 17 reported scalp pain during treatment
[98,102,118,145], 7 reported mild transient headaches, plus 2 studies
with an unstated number of headaches [106,112,117,142,145],
1 reported transient tinnitus [102], 1 reported nausea [112], and
1 reported transient increase in pre-existing back pain [113]. Due to
their low rate of occurrence, transient nature, and complete lack of
need for medical intervention these adverse events can be consid-
ered of minimal risk to the patient.
A further caveat concerns other potential risks in the PD popu-
lation. First, medications should be carefully screened to ensure that
medications associated with a lowered seizure threshold (e.g. anti-
psychotics, psychostimulants, tricyclic antidepressants, buproprion)
are either excluded or carefully monitored. This would include an-
tipsychotics and certain antidepressants. Second, PD patients should
be screened as other patients for associated comorbidities including
cardiac disease and epilepsy. Finally, patients with vascular Parkin-
sonism may have an increased risk of seizure.
We conclude that established TMS protocols have aminimal risk
of adverse events in the PD patient population. PD patients should
still be warned of the potential risk for seizure due to rTMS in the
general population as well as a small risk of transient headache andscalp pain seen in previous PD study participants. However, the use
of TMS should be encouraged in the further study of the neuronal
processes underlying PD as well as an alternative treatment for PD
so long as it is thought to produce clinically relevant improvements
in motor function.Funding agencies
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